This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q64.1 | Special Copayment Reduction: V227 (rare disease Special Copayment Reduction) |
| B. Synonyms | Bladder exstrophy | Ectopia vesicae | Exstrophia vesicae |
| C. Adult onset | Likelihood of first onset in adulthood very low — Bladder exstrophy is a congenital anomaly in which the bladder mucosa is directly exposed through the abdominal wall at birth, so it is diagnosed immediately in the neonatal period. Diagnosis is virtually never delayed until adulthood, and it is not a disease that newly appears in adulthood. |
| 1. History | A congenital abdominal wall anomaly recorded since ancient times. 1898: description of the Trendelenburg procedure. 1942: Higgins primary bladder closure. 1958: Jeffs et al. established the modern staged reconstruction concept. Today, three-stage reconstruction of neonatal primary closure + bladder neck reconstruction + hypospadias repair is the standard. |
| 2. Causes | Failure of abdominal wall closure in the umbilical-pubic midline at 4~6 weeks of embryonic development. Premature rupture or excessive enlargement of the cloacal membrane. Single-gene cause unknown. Candidate genes such as CASPR3·ISL1; increased risk reported with maternal folate deficiency, twins, and assisted reproduction. |
| 3. Genetics | Mostly sporadic. Familial recurrence rate about 1%. Males 1/10,000~1/50,000 births, females 1/25,000~1/100,000. Sibling recurrence risk about 400 times that of the general population. 5.6-fold increased risk reported with assisted reproduction (IVF). |
| 4. General epidemiology | 1 in 10,000~50,000 births (male predominance, M:F ≈ 2~3:1). Part of the bladder exstrophy-hypospadias complex (BEEC). An estimated 1,500~2,000 births per year worldwide. An ultra-rare disease in Korea, with limited accurate national statistics. |
| 5. Pathophysiology | Embryonic weeks 4~7: the cloacal membrane develops excessively and blocks midline mesodermal migration in the lower abdomen. As a result, abdominal wall muscle·bone does not form, and the anterior bladder wall is exposed outside the abdominal wall. Accompanied by pubic symphysis diastasis, open urethra, and genital anomalies. |
| 6. Symptoms | At birth, exposed bladder mucosa in the lower abdomen (red, velvety appearance). Ureteral orifices visible. Boys: hypospadias, short penis·dorsal chordee. Girls: bifid clitoris, short·open vagina. Pubic symphysis diastasis. Bilateral inguinal hernias common. Urinary incontinence after the neonatal period. |
| 7. Signs | Exposed bladder mucosa in the abdominal midline, continuous urine leakage. Pelvic X-ray: pubic symphysis diastasis (4~8 cm). Dorsal chordee·short penis (male). Bifid clitoris (female). Abnormal umbilical position (short umbilical-pubic distance). Upper urinary tract ultrasound may show hydronephrosis. |
| 8. Screening | Suspected on prenatal ultrasound (detailed scan at 18~20 weeks) from nonvisualization of the bladder·lower abdominal wall abnormality·genital abnormality. Can be further confirmed by MRI. Diagnosed immediately after birth by gross findings. Chromosomal·gene panel testing is for excluding associated anomalies. |
| 9. Diagnosis | Clinical diagnosis at birth (gross findings are sufficient). Prenatal: ultrasound + fetal MRI. Postnatal: kidney·ureter·bladder ultrasound, voiding cystourethrography (VCUG), pelvic X-ray, urodynamic study. Additional imaging to evaluate associated anomalies (cardiac, spinal, intestinal). |
| 10. Treatment | Modern standard: three-stage reconstructive surgery. Stage 1 (neonatal period): bladder closure + abdominal wall closure + pelvic osteotomy. Stage 2 (1~2 years): bladder neck reconstruction (Young-Dees-Leadbetter procedure). Stage 3 (after 4~5 years): hypospadias repair. Voiding training, treatment to increase bladder capacity. |
| 11. Prognosis | High survival after neonatal surgery. Rate of achieving social continence: about 70~80% after staged reconstruction (with sufficient bladder capacity). With insufficient bladder capacity, clean intermittent catheterization (CIC) or bladder augmentation is needed. Renal function, reproductive function, and quality of life are key to long-term prognosis. |
| 12. Prevention | After prenatal diagnosis, plan delivery at a specialized center (multidisciplinary pediatric urology·plastic surgery·orthopedics). Folic acid supplementation (recommended before·during pregnancy). Family genetic counseling. Connection to patient support groups. Regular postoperative follow-up (renal function, urinary tract infection, bladder capacity). |
| 13. References | Gearhart JP & Mathews R. Exstrophy-epispadias complex. In: Wein AJ, ed. Campbell-Walsh Urology, 2016 … and 9 other references |
Bladder exstrophy is a congenital anomaly recorded since very early in human history, and its characteristic appearance—bladder mucosa directly exposed in the central abdominal wall—has attracted the attention of physicians and anatomists since ancient times. The Hippocratic writings of the 5th century BC mention infants with abdominal wall abnormalities, and cases resembling bladder exstrophy are also described in the records of 16th-century European anatomists. Before the 19th century, no treatment existed for this disease, and surviving patients led extremely difficult lives due to skin damage and infection from continuous urine leakage and social isolation.
With the development of modern surgery, serious attempts to treat bladder exstrophy began. In the 1890s, the German surgeon Friedrich Trendelenburg described a surgical approach using the pubic symphysis diastasis, laying the foundation for bladder closure. In 1894, the British surgeon Marshall attempted primary closure of the bladder mucosa, but the complication rate was high. In the early 20th century, in 1942, Chester Higgins at Johns Hopkins Hospital in the US advanced the technique of primary bladder closure, and many surgeons subsequently made repeated improvements.
The most important advance in modern bladder exstrophy surgery was made in 1958 by the American pediatric urologist Robert D. Jeffs and colleagues. Going beyond simple bladder closure, he established the concept of staged reconstruction including bladder neck reconstruction, urethroplasty, and genital reconstruction. The bladder neck reconstruction of Young·Dees·Leadbetter has since been used as part of the standard procedure to this day. In the 1980s~90s, combining pelvic osteotomy reduced the pubic symphysis diastasis and lowered abdominal wall closure tension, greatly improving surgical success rates.
In the 21st century, as centralized multidisciplinary treatment at specialized centers such as Johns Hopkins Hospital in the US and Great Ormond Street Hospital (GOSH) in the UK has become the international standard, patient outcomes have continued to improve. Advances in prenatal ultrasound have made prenatal diagnosis possible, enabling planned delivery at specialized centers, immediate surgical preparation, and parent education. Currently in Korea, multidisciplinary pediatric urology·pediatric surgery teams at major university hospitals such as Asan Medical Center and Seoul National University Hospital handle staged reconstruction of bladder exstrophy, and it is registered under National Health Insurance Special Copayment Reduction V227, reducing the burden of medical costs.
The fundamental cause of bladder exstrophy lies in an abnormality of abdominal wall formation in early embryonic development, specifically about 4~7 weeks after fertilization. In normal development, the abdominal wall below the umbilicus is formed as the lateral mesoderm migrates and fuses toward the lower abdominal midline; in bladder exstrophy this process fails, and the central lower abdominal wall is not sufficiently filled with mesoderm. As a result, the cloacal membrane—a thin membrane separating the abdominal cavity from the outside in the early embryo—becomes excessively enlarged or ruptures prematurely, exposing the anterior bladder wall outside the abdominal wall.
The molecular mechanism of abnormal cloacal membrane development has not yet been fully elucidated, but signaling pathways involved in mesodermal migration have drawn attention in several animal models and human studies. Variants or abnormal expression of genes such as CASPR3 (Contactin-associated protein-like 3), ISL1 (Islet-1), and TP63 have been reported in some families with bladder exstrophy, but because a single-gene cause has not been identified in most patients, a multifactorial cause is accepted as the main pathogenetic mechanism.
As environmental risk factors, maternal folate deficiency has been reported in some studies to be associated with increased risk, and there are study results that the risk of bladder exstrophy increases about 5.6-fold with assisted reproductive technology (ART), particularly in vitro fertilization (IVF). This suggests that artificial manipulation during early embryonic development may affect cell migration and differentiation. In addition, discordance (only one of a pair affected) is sometimes observed in monozygotic twins, suggesting that environmental·epigenetic factors act in addition to genetic predisposition.
Bladder exstrophy occurs alone or as part of the Bladder Exstrophy-Epispadias Complex (BEEC) together with epispadias·cloacal exstrophy (OEIS complex). Cloacal exstrophy is a more severe phenotype than bladder exstrophy, accompanied by exposure of the large·small intestine outside the abdominal wall and spinal cord abnormalities (myelomeningocele), and an association with 22q11 deletion has also been reported. Across the entire phenotypic spectrum of BEEC, the combined action of multiple genes·environmental factors rather than a single-gene cause is understood to be the main cause.
The inheritance pattern of bladder exstrophy does not follow simple Mendelian inheritance, and in most cases it occurs sporadically. The familial recurrence rate is low at less than about 1%, but the risk of recurrence in siblings is estimated to be about 400 times higher than the general population incidence. When a patient with bladder exstrophy has a child, the child's risk of being affected is reported as about 1/70 (about 1.4%), and risk assessment in genetic counseling is based on this figure.
The sex distribution shows a clear male predominance (M:F ≈ 2~3:1), which is presumed to be related to sex-based anatomical differences during embryonic development (in boys, urethral length and penile structure are more intricately involved in lower abdominal wall formation during development). It occurs relatively less often in girls, and when it does, the clinical presentation is somewhat different (bifid clitoris, open vagina, etc.).
In molecular genetic studies, deletions of the CASPR3 gene (3p14.2) have been repeatedly identified in families with bladder exstrophy; this gene is involved in cell-cell adhesion and neural·epithelial development. In addition, genome-wide association studies (GWAS) have reported that common variants in the 14q22.3 and 19p13.12 chromosomal regions are associated with bladder exstrophy. The ISL1 transcription factor is essential for mesoderm formation, and loss of ISL1 function in animal experiments induces a bladder exstrophy-like phenotype. However, because these variants alone do not sufficiently explain the occurrence of bladder exstrophy, a complex genetic model in which interactions of many small-effect variants and environmental factors contribute to disease is supported.
Whole-genome sequencing (WGS) and single nucleotide polymorphism (SNP) array studies have shown increased copy number variations (CNV) in patients with bladder exstrophy, with recurrent CNVs observed particularly in the 9p24.1, 1q43, 3p14 regions. In addition, epigenetic studies have reported abnormal DNA methylation patterns in gene regions related to bladder·genitourinary development, supporting the possibility of environment-gene interactions. In cloacal exstrophy (OEIS complex), chromosome 22q11 deletion is rarely present, so chromosomal testing is recommended in this spectrum. Currently, molecular diagnosis of bladder exstrophy is adjunctive to clinical diagnosis and is used for research purposes or estimating familial recurrence risk.
Bladder exstrophy is among the rarer congenital genitourinary anomalies, occurring worldwide at a frequency of about 1 in 10,000~50,000 births. The somewhat different incidence estimates across the literature result from differences in diagnostic criteria, intensity of prenatal screening, and regional reporting systems. The most frequently cited incidence is 1 in 30,000~40,000 births, by which about 1,500~2,000 new cases are estimated to be born worldwide each year.
Sex distribution: Bladder exstrophy is more common in boys, with a reported male-to-female ratio of about 2~3:1. In girls it presents in a form accompanied by bifid clitoris and vaginal abnormalities, and abnormal external genital appearance is clinically prominent. Including the entire bladder exstrophy-epispadias complex (BEEC), the incidence is somewhat higher; when cases with epispadias alone are counted separately, it is about 1 in 120,000 births. Cloacal exstrophy is much rarer than bladder exstrophy, estimated at 1 in 200,000~400,000 births.
Regional epidemiology: The incidence of bladder exstrophy is reported to differ somewhat by race·region, tending to be reported somewhat higher in white populations and lower in Asian·African populations, but this also reflects differences in diagnostic·reporting systems. An increasing trend in bladder exstrophy has been partly observed in developed countries where the use of assisted reproduction is increasing, supporting the hypothesis of ART-related increased risk. Epidemiology in Korea: In Korea, accurate registry statistics have not yet been systematized, but the annual number of new bladder exstrophy cases estimated from National Health Insurance claims data is around 10 per year, making it an ultra-rare disease. Patients registered under National Health Insurance Special Copayment Reduction (V227) can receive a reduction of part of their medical costs. To improve access to specialized multidisciplinary treatment, establishment of a bladder exstrophy registry and designation of specialized centers are also needed in Korea.
Recurrence risk and epidemiological characteristics: Although it mostly occurs sporadically, when a parent is affected, the child's risk of being affected rises to about 1/70 (about 1.4%), so genetic counseling is important. Because discordance is observed in twins, it is confirmed that non-genetic factors also contribute to the disease. Sex and the use of assisted reproduction are the most significant epidemiological risk factors known to date.
To understand the pathophysiology of bladder exstrophy, an understanding of normal embryonic lower abdominal wall formation must come first. About 3~4 weeks after fertilization, during folding of the embryo's trilaminar disc, the lateral plate mesoderm migrates and proliferates toward the midline below the umbilicus to form the muscle layers and connective tissue of the lower abdominal wall. At the same time, the cloacal membrane is located in the midline below the umbilicus and functions as a thin membrane separating the lumens of the genitourinary system and gut from the outside.
The key abnormality in bladder exstrophy is abnormal overexpansion or premature rupture of the cloacal membrane. Normally, mesoderm should migrate around and fill in the cloacal membrane to form the abdominal wall, and the cloacal membrane should be absorbed inward; in bladder exstrophy, however, the cloacal membrane enlarges excessively before abdominal wall formation and becomes a physical barrier to mesodermal migration. Consequently, the muscle·connective tissue·skeleton of the lower abdominal wall are deficient in the midline, and when the cloacal membrane ruptures, the bladder mucosa is directly exposed outside the abdominal wall. This is called the 'overdevelopment of the cloacal membrane theory' of bladder exstrophy.
The mechanism of pubic symphysis diastasis in bladder exstrophy is due to poor pubic bone formation from deficient mesoderm in the lower pelvis and persistent mechanical separation due to bladder exposure. Abnormal development of the external obturator and urogenital diaphragm is also present, so the anatomical positions of the bladder neck and urethral sphincter differ greatly from normal. Epispadias occurs in boys because the corpus spongiosum and corpora cavernosa fail to fuse properly on the upper side. In girls, the open urethra, bifid clitoris, and abnormal labia minora attachment are explained by a similar developmental mechanism.
At the molecular level, animal models suggest that abnormalities in the BMP (bone morphogenetic protein) signaling pathway, FGF receptor signaling, and the Wnt pathway may affect mesodermal migration and differentiation. In particular, a bladder exstrophy-like phenotype was observed in a BMP4-overexpressing mouse model, and dysregulated BMP signaling has been proposed as one of the molecular mechanisms of the disease. In addition, abnormal expression of cell adhesion molecules (E-cadherin, N-cadherin) and basement membrane proteins (laminin, fibronectin) has been reported in human fetal bladder exstrophy tissue, suggesting that abnormal epithelial-mesenchymal cell interactions are related to failure of abdominal wall formation.
The clinical symptoms of bladder exstrophy appear immediately and clearly at birth, taking the form of a complex anomaly in which multiple anatomical structures are abnormal simultaneously. The most central symptom common to all patients with bladder exstrophy is direct exposure of the bladder mucosa in the central lower abdominal wall, which can be seen immediately with the naked eye. The exposed bladder mucosa, when fresh, has a red, velvety surface, and the ureteral orifices are directly visible. Urine continuously flows from the bladder mucosal surface, irritating the skin of the lower abdomen, perineum, and thighs and causing skin redness, maceration, and odor.
Symptoms in boys: Epispadias is present, with the dorsal surface of the urethra open, and the penis is short and bent upward (dorsal chordee). The glans is flat and wide, and the corpora cavernosa are separated on both sides of the exposed bladder area. In boys with bladder exstrophy, severe abnormality of penile appearance has a major impact on adult sexual function, reproductive function, and psychosocial health. Undescended testes, with both testes located in the abdomen or remaining in the inguinal canal, are common.
Symptoms in girls: The clitoris is split into two parts (bifid clitoris) separated left and right, and the labia minora and labia majora are spread wider than normal. The vaginal opening is short or displaced anteriorly, and the uterus and ovaries are usually in normal position. In girls, careful obstetric planning is needed for vaginal delivery in adulthood.
Pubic symphysis diastasis and pelvic abnormalities: In all patients with bladder exstrophy the pubic symphysis is separated (diastasis of 4~8 cm), and the external obturator is rotated anteriorly, causing an externally rotated gait. The umbilicus is located lower than normal or adjacent to the upper edge of the exposed bladder. Bilateral inguinal hernias are commonly present.
Urinary incontinence and upper urinary tract abnormalities: Before primary surgery, bladder neck·sphincter function is absent, so urinary incontinence persists. Even after surgery, incontinence may not resolve completely depending on bladder capacity and function. Vesicoureteral reflux (VUR) is present in nearly all patients with bladder exstrophy, due to abnormal ureteral drainage and bladder neck dysfunction. If left untreated, there is a risk of recurrent urinary tract infections and kidney damage.
The physical signs of bladder exstrophy can be identified immediately at birth and provide direct grounds for clinical diagnosis. The most prominent sign on neonatal physical examination is the bladder mucosa exposed in the central lower abdominal wall, 3~8 cm in diameter, with a red, moist, velvety surface. The ureteral orifices are visible to the naked eye on the bladder mucosal surface, and urine is continuously secreted. When the exposed bladder is gently pressed with a finger, it is often reducible backward.
Pelvic and pubic signs: Pelvic X-ray shows pubic symphysis diastasis, with a separation distance in the range of 4~8 cm. The hip joints are rotated laterally, so the child tends to walk with legs apart and toes pointed outward, which is called an externally rotated gait. The degree of pubic symphysis diastasis is important for treatment planning, particularly in deciding whether to perform pelvic osteotomy.
Signs in boys: Due to epispadias, the urethra is open on the dorsal surface of the penis, and the penis is short with prominent dorsal chordee. The glans is flat and wide, and the corpora cavernosa are separated on both sides. The scrotum is shallow and flat, and bilateral undescended testes are commonly present. An inguinal hernia is palpable.
Signs in girls: Bifid clitoris, separation of the labia minora·labia majora, and anterior displacement of the vaginal opening are observed. The external genitalia appear markedly different from normal. The distance between the clitoris and labia minora is increased. Vaginal length may be short, but the uterus·ovaries are usually normal.
Laboratory·imaging findings: Kidney·ureter·bladder (KUB) ultrasound may show hydronephrosis, ureteral dilation, and abnormal bladder size. Voiding cystourethrography (VCUG) confirms vesicoureteral reflux. Baseline renal function is assessed by renal function evaluation (serum creatinine, renal nuclear medicine scan DTPA or DMSA). Urodynamic study is used to evaluate bladder capacity, compliance, and sphincter function. Preoperative MRI helps evaluate pelvic anatomy and genital structures.
Screening for bladder exstrophy is mainly done by prenatal ultrasound, and after birth an immediate clinical diagnosis is possible from gross findings alone. There is no newborn screening program for the general population, but as prenatal ultrasound has become universal worldwide, prenatal screening functions as the de facto main screening tool.
Prenatal ultrasound screening: The main findings suggesting bladder exstrophy on the detailed ultrasound (targeted ultrasound or anomaly scan) performed at 18~20 weeks of gestation are as follows. ① Bladder non-visualization: the bladder, which should be visible in a normal fetus, is not seen even on repeated examinations. ② Lower abdominal mass: an abnormal soft tissue protrusion is seen in the area corresponding to the bladder position. ③ Genital abnormalities: in boys, a short penis bent upward; in girls, bifid clitoris or abnormal external genital structures. ④ Abnormal umbilical position: the umbilicus is located lower than normal. ⑤ Pubic symphysis diastasis: increased distance between the pelvic bones. The sensitivity of prenatal ultrasound for detecting bladder exstrophy is reported as about 50~70% at specialized centers, but this depends greatly on examiner experience and fetal position.
Fetal MRI: When bladder exstrophy is suspected on ultrasound, fetal MRI allows more detailed evaluation of pelvic anatomy, genital structures, spine, and bowel. MRI is particularly useful for differentiation from cloacal exstrophy and for checking for associated spinal cord abnormalities.
Prenatal genetic testing: There is no standardized prenatal genetic test for bladder exstrophy itself, but fetal chromosomal testing (G-band karyotyping, chromosomal microarray) is recommended when associated anomalies are suspected or in the cloacal exstrophy spectrum. FISH or microarray testing is needed particularly in cloacal exstrophy associated with 22q11 deletion.
Postnatal confirmation of diagnosis: Once the clinical diagnosis is confirmed right after birth, the bladder mucosa is immediately protected with a non-adherent dressing moistened with saline to prevent mucosal damage and infection, and the patient is referred to a specialized multidisciplinary team (pediatric urology, pediatric surgery, pediatric orthopedics, pediatric neurosurgery, neonatology). Kidney·ureter ultrasound is performed immediately to check for associated upper urinary tract anomalies.
The diagnosis of bladder exstrophy is fully possible from the characteristic clinical findings at birth alone, and additional tests are performed to evaluate associated abnormalities, plan surgery, and monitor renal function. Prenatally, a suspected diagnosis is made by ultrasound and fetal MRI, and it is confirmed on physical examination right after birth.
Clinical diagnostic criteria: Bladder exstrophy is clinically diagnosed when exposure of the bladder mucosa in the lower abdominal midline, direct visualization of the ureteral orifices, continuous urine secretion, pubic symphysis diastasis, and genital abnormalities (boys: epispadias·short penis·dorsal chordee; girls: bifid clitoris·vaginal abnormalities) are present simultaneously.
Imaging studies: Kidney·ureter·bladder ultrasound is performed within 24 hours after birth to evaluate hydronephrosis, ureteral dilation, and associated renal anomalies. Pelvic X-ray measures the pubic symphysis diastasis distance and evaluates pelvic shape, an important indicator in deciding whether to apply pelvic osteotomy. MRI is used for detailed preoperative evaluation of pelvic anatomy, the structure of the sphincter complex, genital structures, and urethral anatomy.
Urodynamic study: Used to evaluate bladder capacity, detrusor activity, and sphincter function, and to compare bladder function before·after surgery. It is also an important test for postoperative voiding training and for predicting the likelihood of achieving continence. When bladder capacity is too small (< 50~60 mL), it affects the timing and method of bladder neck reconstruction surgery.
Voiding cystourethrography (VCUG): Evaluates the presence and grade of vesicoureteral reflux (VUR), and VUR is found in most patients with bladder exstrophy. The VUR grade determines prophylactic antibiotic use and the timing of surgical correction.
Renal nuclear medicine studies: DTPA (diethylenetriamine pentaacetate) or MAG3 renography evaluates the split function and drainage pattern of each kidney, and DMSA (dimercaptosuccinic acid) renal scan evaluates renal scarring. With recurrent urinary tract infections, periodic DMSA scans are recommended to monitor renal scarring.
Genetic·chromosomal testing: These tests are not essential in isolated bladder exstrophy, but chromosomal microarray testing is recommended with cloacal exstrophy or multiple congenital anomalies. Molecular diagnosis of bladder exstrophy itself is at the research stage and is used only as an adjunct to clinical diagnosis.
The core of treatment for bladder exstrophy is staged surgical reconstruction that systematically corrects multiple anatomical abnormalities, and cooperation of a multidisciplinary team including pediatric urology·pediatric surgery·pediatric orthopedics·pediatric plastic surgery·pediatric neurosurgery·pediatric anesthesiology·neonatology is essential. The current standard treatment, Modern Staged Repair of Exstrophy (MSRE), and an alternative approach, Complete Primary Repair of Exstrophy (CPRE), are used in parallel.
Stage 1: Neonatal bladder closure and abdominal wall closure (within 48~72 hours after birth): The exposed bladder is returned into the abdominal cavity and the anterior bladder wall is closed·reconstructed. At the same time, the abdominal wall defect is closed, and if the pubic symphysis diastasis is 4 cm or more, pelvic osteotomy (iliac osteotomy or pubic ramus osteotomy) is performed to bring the pubic bones to the midline and reduce closure tension. After osteotomy, the bladder can be seated in an appropriate position in the abdominal cavity, increasing surgical success. After surgery, both legs are immobilized for about 4~6 weeks with skin traction or a spica cast.
Stage 2: Bladder neck reconstruction and ureteral reimplantation (1~2 years, when bladder capacity is sufficient): After bladder capacity has increased sufficiently (generally about 60~100 mL or more), Young-Dees-Leadbetter bladder neck reconstruction is performed. This procedure reshapes the bladder neck to increase urethral resistance and promote continence. At the same time, Cohen or Politano-Leadbetter ureteral reimplantation is performed to correct vesicoureteral reflux (VUR). Antireflux ureteral reimplantation aims to protect the upper urinary tract and prevent recurrent urinary tract infections.
Stage 3: Hypospadias repair and genital reconstruction (after 4~5 years): In boys, epispadias repair (urethroplasty, correction of penile curvature, glanuloplasty) is performed. In girls, vaginal reconstruction and closure of the bifid clitoris are performed. This stage aims for completion before school age to achieve social continence before school life and minimize psychological effects.
Treatment to increase bladder capacity: If bladder capacity remains insufficient even after staged surgery, bladder augmentation (mainly using ileum or colon) is performed, and clean intermittent catheterization (CIC) is applied. The Mitrofanoff procedure (creating a catheterizable channel using the appendix or ileum) enables catheterization through the abdominal wall in patients with difficult urethral access.
Postoperative management and follow-up: Prevention of urinary tract infection (prophylactic antibiotics), follow-up of bladder function (urodynamic study, ultrasound), monitoring of renal function (serum creatinine, renal nuclear medicine scans), growth monitoring, and psychosocial support are needed over the long term. After puberty, ongoing counseling and support regarding sexual function·reproductive function·quality of life are important.
The prognosis of bladder exstrophy has greatly improved with advances in modern surgical techniques and multidisciplinary management. Neonatal surgical mortality is very low at specialized centers (< 1%), and most patients survive into adulthood. However, achieving continence, preserving renal function, sexual and reproductive function, and quality of life are managed as key indicators of long-term prognosis.
Achieving continence: After staged reconstructive surgery, the rate of achieving socially acceptable continence (voiding interval of 4 hours or more, at least dry at night) is reported as about 70~80% at specialized centers. The most important predictor of achieving continence is adequate development of bladder capacity after primary surgery. When bladder capacity is insufficient or continence is not achieved even after bladder neck reconstruction, bladder augmentation and clean intermittent catheterization (CIC) are alternatives.
Renal function: Renal scarring due to recurrent urinary tract infections and vesicoureteral reflux is the main cause of long-term decline in renal function. Renal function can be preserved through antireflux ureteral reimplantation, prophylactic antibiotics, and regular renal function monitoring. The proportion maintaining normal renal function into adulthood is reported as about 80~90% or more, but this depends greatly on the thoroughness of follow-up.
Sexual and reproductive function: In boys, penile function, urethral fistula, stricture, and erectile function after urethroplasty are important items of long-term follow-up. Erectile function is generally preserved in adulthood, but intercourse may be difficult if penile curvature is not fully corrected. In girls, pregnancy·vaginal delivery in adulthood are possible, but because of the risk of complications from abnormal pelvic floor structure, planned delivery (cesarean section or specialized obstetric care) is recommended. In boys, reproductive function (sperm motility, fertility) may be partly reduced due to urethral surgery and possible seminal vesicle damage.
Psychosocial prognosis: Psychological trauma from abnormal genital appearance, urinary incontinence, and repeated surgeries has an important impact on quality of life. Early psychological support, peer support groups, and counseling at each developmental stage are essential for maintaining psychosocial health. Long-term follow-up studies report that many patients can lead lives similar to the general population in adult employment, social relationships, and sexual activity.
Complete primary prevention of bladder exstrophy is currently not possible, but referral to specialized centers through prenatal diagnosis, folic acid supplementation, genetic counseling, and prevention of postoperative complications are recommended as currently available prevention strategies.
Prenatal diagnosis and referral to specialized centers: When bladder exstrophy is suspected on detailed prenatal ultrasound, the mother is immediately referred to a specialized multidisciplinary bladder exstrophy center to establish a delivery plan. Planned delivery at a specialized center enables immediate bladder protection right after birth, neonatal stabilization, and preparation of the surgical team, and is reported to improve surgical outcomes. Both vaginal delivery and cesarean section are possible, but it is important that delivery takes place under the plan of a specialized center.
Folic acid supplementation: Taking folic acid 0.4~0.8 mg/day (4 mg/day for high-risk groups) from at least 3 months before pregnancy through early pregnancy (12 weeks) is known to reduce the risk of several congenital anomalies including neural tube defects, and since some studies have reported an association between folic acid supplementation and reduced risk of bladder exstrophy, it is recommended.
Caution regarding assisted reproduction: Since it has been reported that in vitro fertilization (IVF) may increase the risk of bladder exstrophy, this information should be fully provided to couples planning assisted reproduction, and detailed prenatal ultrasound should be performed thoroughly.
Prevention of postoperative complications (tertiary prevention): Urinary tract infections are prevented with postoperative prophylactic antibiotics, and kidney damage is minimized through regular follow-up (renal function, bladder function, VUR). Bladder voiding training and physical therapy help achieve continence, and psychological counseling prevents psychological complications. A social support network is built by connecting families with patient support organizations (e.g., bladder exstrophy·epispadias associations).
Genetic counseling: For patients with bladder exstrophy or those with a family history, thorough counseling with a genetic counselor on familial recurrence risk (about 1%), prenatal screening methods, and available testing options should be provided. With future advances in molecular diagnostic technology, targeted genetic testing for high-risk families is expected to become possible.
Gearhart JP, Mathews R. Exstrophy-epispadias complex. In: Wein AJ, Kavoussi LR, eds. Campbell-Walsh Urology, 11th ed. Elsevier; 2016:3182-3220.
Ebert AK, Reutter H, Ludwig M, Rösch WH. The exstrophy-epispadias complex. Orphanet J Rare Dis. 2009;4:23. DOI: 10.1186/1750-1172-4-23. PMID: 19878548.
Cervellione RM, Mantovani A, Gearhart JP. Review of the staged and complete repair approaches for bladder exstrophy. J Pediatr Urol. 2015;11(5):267-274. DOI: 10.1016/j.jpurol.2015.06.005. PMID: 26276502.
Merrot T, Chaumoitre K, Bouillot R, et al. Antenatal diagnosis of bladder exstrophy. J Pediatr Urol. 2012;8(3):e43-e47. DOI: 10.1016/j.jpurol.2012.01.007. PMID: 22386742.
Ludwig M, Reutter H, Boyadjiev SA. Genetics of bladder exstrophy-epispadias complex (BEEC): systematic review and meta-analysis. J Pediatr Urol. 2009;5(6):499-504. DOI: 10.1016/j.jpurol.2009.05.011. PMID: 19833549.
Gargollo PC, Borer JG, Diamond DA, et al. Prospective follow-up in patients after complete primary repair of bladder exstrophy. J Urol. 2008;180(4 Suppl):1665-1670. DOI: 10.1016/j.juro.2008.03.030. PMID: 18721931.
Greenwell TJ, Venn SN, Creighton S, et al. Augmentation cystoplasty for bladder exstrophy and epispadias. BJU Int. 2003;91(7):659-663. DOI: 10.1046/j.1464-410x.2003.04188.x. PMID: 12699480.
Boyadjiev SA, Dodson JL, Radford CL, et al. Clinical and molecular characterization of the bladder exstrophy-epispadias complex: analysis to determine the mode of inheritance. BJU Int. 2004;94(9):1337-1344. DOI: 10.1111/j.1464-410X.2004.05166.x. PMID: 15610115.
Siffel C, Correa A, Amar E, et al. Bladder exstrophy: an epidemiologic study from the International Clearinghouse for Birth Defects Surveillance and Research, and an overview of the literature. Am J Med Genet C Semin Med Genet. 2011;157C(4):321-332. DOI: 10.1002/ajmg.c.30316. PMID: 21910217.
Diamond DA, Chan IH, Holland AJ, et al. Advances in paediatric urology. Lancet. 2017;390(10099):1061-1071. DOI: 10.1016/S0140-6736(17)32282-2. PMID: 28776563.